Abstract. Hepatitis C is the commonest form of chronic viral hepatitis in most western countries. A significant proportion of patients develop cirrhosis, hepatic failure and hepatocellular carcinoma. The results of controlled trials have shown that interferon a is an effective treatment for hepatitis C. Treatment results in normalization of elevated transaminase levels in up to 50% of patients, although only 15-25% of patients have a sustained response. Recent studies have shown that iron influences the response of chronic hepatitis C to treatment and the natural history of hepatitis C. The mechanisms responsible for the effects of iron are not clear but emerging data suggest that the cellular location of iron within the liver lobule and the subsequent effects on immune function are likely to be critical determinants for these effects. It is likely that therapies for chronic hepatitis C which either remove iron or interfere with the action of iron at the cellular level may not only prove useful clinically but may also elucidate further the mechanisms of cellular injury in this disease. (Keio J Med 48 (3): 124-131, September 1999)
Introduction
Hepatitis C has emerged as the commonest form of chronic viral hepatitis in most developed countries and predisposes patients to the development of cirrhosis, hepatic failure and hepatocellular carcinoma. Clinical trials have shown that interferon a is an effective treat ment for hepatitis C. Treatment results in normalization of elevated transaminase levels in up to 50% of patients, although only 15-25% of patients have a sus tained response.1-3 Furthermore, interferon a is costly with well-documented side effects. Thus, there is a need to identify alternative or complementary therapies which increase the proportion of patients who have a sustained response. Well characterized pretreatment characteristics of response include age, sex, duration of infection, mode of acquisition, liver histology, hepatitis C virus (HCV) RNA levels and genotype.4-11 More recently, considerable interest has been generated re garding the role of iron in the pathogenesis of chronic hepatitis C and the role of de-ironing therapies as an adjunctive treatment for chronic liver disease which results from HCV infection. Whilst iron is an essential element for the survival of cells, excess amounts can result in tissue injury.12 It is now apparent that iron can also modulate disease states and cellular function at levels much below those observed in classical iron overload. The aim of this article is to review the current state of knowledge pertaining to the role of iron in chronic hepatitis C.
Serum and Hepatic Iron Studies in Hepatitis C
The study of serum and hepatic iron parameters in chronic liver disease is readily achieved through the use of several standard methods. Serum transferrin satura tion and ferritin levels, whilst useful in the assessment of iron overload in conditions such as hereditary hemochromatosis, are not as useful in the determina tion of iron status in chronic inflammatory liver diseases due to the effect of inflammation and pro-inflammatory mediators on serum iron levels and hepatic transferrin and ferritin synthesis.13 The gold standard for defining hepatic iron content is biochemical measurement of the non-heme hepatic iron concentration (HIC) .14 The HIC can be determined from fresh or paraffin embedded tissue 
HFE Mutations and Hepatitis C
The recent discovery of the HFE gene containing two missense mutations (C282Y and H63D) which are strongly associated with disordered iron metabolism raises the possibility that abnormal HFE genotypes could contribute to iron-related cell injury in chronic hepatitis C.46 Recent studies have analysed the rela tionship of HFE mutations and iron overload in chronic hepatitis C.46-49 Patients with hepatitis C have fre quencies of HFE mutations that are no different than the general population. However , heterozygosity for the C282Y mutation is often associated with increased iron stores and with more advanced liver fibrosis .50 There is a much stronger association between HFE gene mutations, abnormal iron status and HCV infec tion in patients with porphyria cutanea tarda .47,51,52 Thus in this group of patients it is possible that iron could play a more significant role in the pathogenesis of hepatitis C-related liver injury , but this remains to be confirmed in prospective studies .
Pathophysiology of Iron Toxicity in Hepatitis C
The mechanisms by which iron may cause liver dis ease have been recently reviewed.12 The concept that iron can act in a synergistic fashion with other hepato cell numbers increase significantly with progression of disease severity in each of the groups studied, suggest ing that oval cell proliferation is not disease specific but occurs in response to progressive liver injury and fib rosis. The association between severity of liver disease and increasing number of oval cells is consistent with the hypothesis that oval cell proliferation is associated with the increased risk for development of hepato cellular carcinoma with advancing liver disease, par ticularly when cirrhosis is present. Finally, iron could contribute to the increased risk of hepatocellular car cinoma in chronic hepatitis C through DNA damage from iron-induced adduct formation and chromosomal damage.73.74
The pathophysiological mechanisms whereby iron exerts its effects in chronic hepatitis C are unknown. Much evidence has accumulated supporting an immu nopathological mechanism which underlies liver injury in chronic hepatitis C.75-77 Virus specific T cells are present in the liver tissue and peripheral blood of patients with HCV infection and are able to contribute to hepatocellular injury, but are not able to eliminate viral infection.78,79 Previous studies have shown that persistent hepatitis B virus infection is associated with iron overload.20,21,80 It is also known that patients with iron overload are more susceptible to bacterial infec tions.81 Iron has been shown to impair antigen-specific immune responses and generation of cytotoxic T-cells, decrease functional T-helper precursor cells, and en hance T-suppressor activity.82,83 Natural killer cell activity has also been reported to be decreased in iron overload conditions .84-86 Lymphocyte proliferation is inhibited by ferritin.87,88 Ferritin molecules, particu larly those rich in heavy (H) subunits, bind to activated T-cells89 and H-ferritin receptors are expressed by T-cell lines.90,91 These data suggest that iron could impair host lymphocyte-dependent clearance of HCV virus. Interferon a possesses multiple actions including direct antiviral effects and enzyme modulation . 92 The actions of IFN are not known to be dependent on intracellular iron although it is possible that iron might also interfere in some way with these actions resulting in a reduced antiviral activity. It has been suggested that transferrin and non-transferrin-bound iron-uptake pathways may be affected in necro-inflammatory con ditions.93 As a result, non-responders might have increased iron uptake and hepatic iron deposition when compared with responders. Increased hepatic iron de position in hepatitis C may then result in increased oxidative stress in the liver , decreased glutathione levels and lipid peroxidation and formation of malondialde hyde adducts .29,32,39,40,56-58 The type of storage mole cule from which iron is released could modulate these effects. It is well known that ferritin and hemosiderin release iron to different degrees , a property which may influence the ability of iron to participate in biological reactions. 94 It is possible that iron deposition in sinusoidal cells, especially Kupffer cells, could alter the immune responsiveness of macrophages. This hypothesis is sup ported by observations that iron deposition within zone 1, portal tracts and sinusoidal lining cells is associated with a higher likelihood of non-response to interferon therapy.27-34 There are reports of impaired phagocytic function by monocytes in hereditary hemochroma tosis.95,96 Intracellular killing of microorganisms may also be impaired by iron overload.96,97 Interleukin 2 production by cytotoxic T-cells is reduced in the pres ence of iron overload. 83 We have studied the effect of chronic iron overload on Kupffer cell cytokine produc tion.98 Kupffer cells from iron loaded animal exhibit reduced proinflammatory cytokine production com pared with Kupffer cells from control animals. Thus iron loading may impair immune clearance mechanisms via impaired macrophage function or interfere with the actions of interferon a on macrophage function.
Iron Status and Likelifood of Response to Interferon Therapy
Following the reports of the relationship between iron status and likelihood of response, investigators be gan evaluating the possibility that patients might benefit by being depleted of iron by repeated therapeutic phlebotomy before treatment with interferon or to improved response rates in previous non-responders. Hayashi et al.34 reported that iron reduction alone led to the normalization of serum ALT levels in 5 of 10 patients with chronic hepatitis C. Four to 13 phleboto mies, with removal of 1-3g of iron, over 2-9 months were required to achieve iron removal as judged by se rum ferritin levels less than 10 ng/ml. Seven patients underwent repeat biopsy within 2 months of iron de pletion, with no apparent change in the severity of portal fibrosis or inflammation. In another study of 8 patients with chronic hepatitis C who had previously failed to respond to treatment with interferon a, serum ALT levels fell in 7 of 8 following iron reduction.38 Van Thiel et al.99 randomized 30 non-responders to iron depletion followed by interferon a or interferon a alone. Twelve of 15 (80%) of patients treated with iron depletion and interferon had a virological response at 6 months compared with 6/15 (40%) in the interferon alone group. Significantly higher sustained virological response rates were seen in the iron depleted group (60%) compared with interferon-alone group (13%). Iron chelation with desferoxamine has also been shown to improve response to interferon therapy.100 How ever, there have been no clear effects of iron reduction on levels of HCV RNA in serum.100-112 Fong et al.43 recently conducted a randomized study which evaluated the effect of iron depletion on amino transferase activity, HCV RNA levels and response to interferon a therapy in patients with chronic hepatitis C. Serum ALT levels decreased in 15 of 17 patients after phlebotomy. Changes in iron indices and ALT levels were not accompanied by changes in HCV RNA levels. At the end of 24 weeks of interferon therapy, similar numbers of phlebotomized patients (7 of 17) had a response compared to control patients (6 of 21). However after 6 months of follow up, 5 of 17 phlebo tomized patients remained HCV RNA negative com pared with 1 of 21 controls (p=0.07). Tsai et al. 103 have also shown that phlebotomy therapy may result in a sustained response in up to 15% of patients who have previously not responded to treatment with interferon but who are retreated following phlebotomy therapy.
Boucher et al.27 provided additional information on the possible relationships between hepatic iron metab olism and chronic hepatitis C. In their study, 55 patients were treated with interferon for six months and the HIC and distribution of iron were evaluated before and after therapy. They found no difference in HIC be tween non-responders and responders. However, they did identify a relation between HIC and inflammatory activity such that the iron load was higher in those patients with the greatest degree of histological inflam matory activity. Interestingly, HIC decreased following treatment with interferon. This was related to iron depleted from sinusoidal cells and was apparent re gardless of whether patients responded to interferon therapy or not. These findings suggest that increased iron stores may be present in patients with chronic hepatitis C predominantly as a result of the degree of inflammatory activity, presumably correlating with cell injury or necrosis, with subsequent phagocytosis by Kupffer cells resulting in progressive increases in Kupffer cell iron loading.
In summary, iron influences the response of chronic hepatitis C to treatment and perhaps the natural history of hepatitis C. The mechanisms responsible for the effects of iron are not clear but emerging data suggest that the cellular location of iron within the liver lobule and the subsequent effects on immune function are likely to be critical determinants for these effects . Con tinued evaluation of therapies for chronic hepatitis C which either remove iron or interfere with the action of iron at the cellular level may not only prove useful clinically but may also elucidate further the mechanisms of cellular injury in this disease . 
